Skip to main content
. 2022 Sep 26;10(10):1613. doi: 10.3390/vaccines10101613

Figure 2.

Figure 2

Figure 2

(A,B) SARS-CoV-2 binding antibody response SARS-CoV-2 binding antibody response at post-third mRNA COVID-19 vaccine following the heterologous CoronaVac/ChAdOx1 vaccination in cancer patients versus healthy controls (A) and aged match subset analysis (B). (C) SARS-CoV-2 binding antibody response at post-third mRNA COVID-19 vaccine following the primary CoronaVac/ChAdOx1 vaccination in cancer patients stratified by types of mRNA COVID-19 vaccines and types of anticancer treatment. (D) Vaccine-related reactogenicity after the CoronaVac/ChAdOx1/mRNA vaccination in cancer patients. a Mann-Whitney test, b Wilcoxon signed rank test.